The contemporary management of peritoneal metastasis: A journey from the cold past of treatment futility to a warm present and a bright future

Ca-A Cancer Journal for Clinicians - Tập 73 Số 1 - Trang 49-71 - 2023
Jason M. Foster1, Chunmeng Zhang1, Shahyan Rehman2, Prateek Sharma1, H. Richard Alexander2
1Division of Surgical Oncology, Department of Surgery, University of Nebraska Medical Center, Omaha, Nebraska, USA
2Division of Surgical Oncology, Rutgers Cancer Institute of New Jersey

Tóm tắt

AbstractPeritoneal metastasis (PM) is often regarded as a less frequent pattern of spread; however, collectively across all spectra of primary tumors, the consequences of PM impact a large population of patients annually. Unlike other modes of metastasis, symptoms at presentation or during the treatment course are common, representing an additional challenge in the management of PM. Early efforts with chemotherapy and incomplete surgical interventions transiently improved symptoms, but durable symptom control and survival extension were rare, which established a perspective of treatment futility for PM through most of the 20th century. Notably, the continued development of better systemic therapy combinations, optimization of cytoreductive surgery (CRS), and rigorous investigation of combining regional therapy—specifically hyperthermic intraperitoneal chemotherapy—with CRS, have resulted in more effective multimodal treatment options for patients with PM. In this article, the authors provide a comprehensive review of the data establishing the contemporary approach for tumors with a high frequency of PM, including appendix, colorectal, mesothelioma, and gastric cancers. The authors also explore the emerging role of adding hyperthermic intraperitoneal chemotherapy to the well established paradigm of CRS and systemic therapy for advanced ovarian cancer, as well as the recent clinical trials identifying the efficacy of poly(adenosine diphosphate ribose) polymerase maintenance therapy. Finally, recent data are included that explore the role of precision medicine technology in PM management that, in the future, may help further improve patient selection, identify the best systemic therapy regimens, detect actionable mutations, and identify new targets for drug development.

Từ khóa


Tài liệu tham khảo

10.1007/s00384-013-1714-9

10.1016/j.ejso.2007.04.002

10.1097/DCR.0b013e3182a62b0d

10.21037/tlcr.2019.11.11

American Society of Clinical Oncology (ASCO) Cancer.Net. Mesothelioma: Statistics. ASCO; 2021. Accessed February 14 2022.cancer.net/cancer‐types/mesothelioma/statistics

10.3802/jgo.2020.31.e58

10.1016/j.ejso.2012.03.008

10.1002/ijc.28373

Abbasi SY, 2011, Advanced gastric cancer in Jordan from 2004 to 2008: a study of epidemiology and outcomes, Gastrointest Cancer Res., 4, 122

10.1007/s10555-020-09924-4

Hernandez DL, 2020, Peritoneal metastasis of cholangiocarcinoma treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy at the Instituto Nacional de Cancerologia, Colombia, Cureus., 12, e6697

10.1002/(SICI)1097-0142(20000115)88:2<358::AID-CNCR16>3.0.CO;2-O

10.1016/S1470-2045(05)70539-8

10.14694/EdBook_AM.2013.33.221

Spratt JS, 1980, Clinical delivery system for intraperitoneal hyperthermic chemotherapy, Cancer Res., 40, 256

10.1097/00000658-199501000-00004

10.1097/00000658-199502000-00002

10.1097/00000478-199512000-00006

10.1200/JCO.2003.04.187

10.1001/archsurg.1997.01430280012001

10.1007/s10585-021-10074-2

10.1016/j.ejso.2018.05.021

10.1016/j.ejso.2018.04.023

10.1245/s10434-012-2240-7

10.1097/01.pas.0000202039.74837.7d

10.1111/his.13324

10.1002/1097-0142(19901001)66:7<1636::AID-CNCR2820660731>3.0.CO;2-N

10.1016/j.suronc.2010.12.001

10.1097/PPO.0b013e3181a9c781

10.1080/02656736.2017.1310938

Meigs JV, 1934, Tumors of the Female Pelvic Organs, The Macmillan Company

10.1016/0002-9610(69)90300-6

10.1016/S0002-9378(15)33580-8

10.1007/BF02642643

Griffiths CT, 1979, Role of cytoreductive surgical treatment in the management of advanced ovarian cancer, Cancer Treat Rep., 63, 235

10.1002/1097-0142(195403)7:2<302::AID-CNCR2820070214>3.0.CO;2-9

10.1001/archsurg.1980.01380040037006

Dedrick RL, 1978, Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer, Cancer Treat Rep., 62, 1

Pretorius RG, 1981, Comparison of the iv and ip routes of administration of cisplatin in dogs, Cancer Treat Rep., 65, 1055

Sugarbaker PH, 1985, Prospective, randomized trial of intravenous versus intraperitoneal 5‐fluorouracil in patients with advanced primary colon or rectal cancer, Surgery., 98, 414

10.1016/j.soc.2010.11.001

10.1245/s10434-013-3145-9

Jacquet P, 1996, Current methodologies for clinical assessment of patients with peritoneal carcinomatosis, J Exp Clin Cancer Res., 15, 49

10.1002/jso.23547

10.1002/cncr.29744

10.1016/j.jamcollsurg.2017.12.027

10.1245/s10434-020-08316-w

10.1016/j.ejso.2020.02.012

10.1186/s13023-021-01723-6

10.1001/jamasurg.2020.6363

10.1097/01.sla.0000152015.76731.1f

10.1007/s10434-999-0727-7

10.1097/01.sla.0000133183.15705.71

10.1097/01.sla.0000231705.40081.1a

10.1245/s10434-009-0341-8

10.1016/j.ejso.2010.01.006

10.1016/j.ejso.2020.11.134

10.1245/s10434-018-7007-3

10.1245/s10434-017-6272-x

10.1245/s10434-018-6560-0

10.1245/s10434-015-4995-0

10.1007/s10434-006-9708-2

10.1002/jso.21679

10.1245/s10434-017-5938-8

10.1007/s11605-019-04336-4

10.1093/annonc/mdr279

10.1016/j.ejso.2015.01.005

10.1007/DCR.0b013e318202f026

10.1200/JCO.2011.39.7166

10.1002/jso.26439

Ang CSP, 2018, Genomic landscape of appendiceal neoplasms. JCO Precis, Oncol.

10.1158/1078-0432.CCR-18-3388

10.3322/caac.21601

10.3322/caac.21654

10.1002/bjs.8679

10.1245/s10434-017-6037-6

10.1016/j.ejso.2013.10.001

10.1056/NEJM199002083220602

10.7326/0003-4819-122-5-199503010-00001

10.1056/NEJMoa032709

10.1200/JCO.2008.20.6771

10.1093/annonc/mdl179

10.1093/annonc/mdm607

10.1200/JCO.2004.09.046

10.1200/JCO.2008.20.4552

10.1200/JCO.2006.09.0928

10.1016/S1470-2045(15)00122-9

10.1200/JCO.2011.37.1039

10.1016/S1470-2045(20)30599-4

10.1007/s002800051093

10.1002/1097-0142(20000601)88:11<2512::AID-CNCR12>3.0.CO;2-J

Hughes KS, 1986, Resection of the liver for colorectal carcinoma metastases: a multi‐institutional study of patterns of recurrence, Surgery., 100, 278

10.1200/JCO.1997.15.3.938

10.1200/JCO.2004.10.012

10.1016/j.jamcollsurg.2006.08.024

10.1245/s10434-008-0127-4

10.1245/s10434-014-3798-z

10.1245/s10434-020-08315-x

10.1016/j.ejso.2018.07.003

10.1016/j.ejso.2015.08.162

10.1016/j.soc.2018.02.009

10.1245/s10434-014-3978-x

10.1245/s10434-014-3803-6

10.1093/annonc/mdf019

10.1200/JCO.2008.19.7160

10.1002/jso.23728

10.3109/02656736.2015.1029995

10.1245/s10434-020-08790-2

Rovers KP, 2019, Perioperative systemic therapy and cytoreductive surgery with HIPEC versus upfront cytoreductive surgery with HIPEC alone for isolated resectable colorectal peritoneal metastases: protocol of a multicentre, open‐label, parallel‐group, phase II‐III, randomised, superiority study (CAIRO6), BMC Cancer., 19, 390, 10.1186/s12885-019-5545-0

10.1016/S2468-1253(19)30239-0

10.1016/S1470-2045(20)30322-3

10.1186/s12885-018-4096-0

10.1186/s12885-019-5408-8

10.3322/caac.21708

10.3322/caac.21456

10.1016/j.ygyno.2018.03.001

10.1056/NEJM199601043340101

10.1200/JCO.2000.18.1.106

10.1200/JCO.2003.02.153

10.1200/JCO.2006.10.2517

10.1038/bjc.2011.382

10.1056/NEJMoa1910962

10.1056/NEJMoa1909707

10.1056/NEJMoa1810858

10.1056/NEJM199612263352603

10.1200/JCO.2001.19.4.1001

10.1056/NEJMoa052985

10.6004/jnccn.2006.0077

10.1002/jso.24406

10.1245/s10434-014-4157-9

10.1200/JCO.21.00605

10.1056/NEJMoa1708618

10.1001/jamasurg.2022.0143

10.3322/caac.21572

10.5858/arpa.2017-0124-RA

10.1093/annonc/mdl060

10.1016/j.jtho.2021.09.012

10.5858/arpa.2017-0365-RA

10.1016/j.surg.2013.01.001

10.3816/CLC.2005.n.020

10.1016/j.lungcan.2008.08.013

10.1016/S0140-6736(15)01238-6

10.1016/S1470-2045(17)30446-1

10.1016/S0140-6736(20)32714-8

10.1038/s41416-020-01130-x

10.1200/JCO.2009.23.9640

10.1016/j.ejca.2013.05.027

10.1245/s10434-013-3358-y

10.1245/s10434-017-5834-2

10.1245/s10434-012-2651-5

10.1200/JCO.2003.04.150

10.1016/j.ejca.2016.06.002

10.1097/PAT.0000000000000181

10.1007/s12032-018-1125-4

10.1245/s10434-007-9701-4

10.1001/jamanetworkopen.2018.6847

10.1245/s10434-010-1080-6

10.3322/caac.21657

10.1007/s11912-019-0820-4

10.1016/j.ejso.2020.02.038

10.1245/s10434-011-1631-5

10.1200/JCO.1989.7.9.1310

10.1002/1097-0142(19911001)68:7<1501::AID-CNCR2820680706>3.0.CO;2-L

10.1056/NEJMoa055531

10.1016/S0140-6736(18)32557-1

10.1016/S0140-6736(10)61121-X

Yonemura Y, 2012, Effects of neoadjuvant intraperitoneal/systemic chemotherapy (bidirectional chemotherapy) for the treatment of patients with peritoneal metastasis from gastric cancer, Int J Surg Oncol., 2012, 148420

10.1002/bjs.1800830605

10.1016/j.suronc.2014.03.004

10.1097/00000658-198807000-00005

10.1007/BF00348209

Yonemura Y, 2001, Intraoperative chemohyperthermic peritoneal perfusion as an adjuvant to gastric cancer: final results of a randomized controlled study, Hepatogastroenterology., 48, 1776

10.1002/jso.23633

10.1200/JCO.2004.08.026

10.1002/cncr.25356

10.1245/s10434-010-1039-7

10.1016/j.gassur.2003.12.014

10.1200/JCO.18.01688

10.1016/S0002-9610(99)00162-2

10.1002/(SICI)1096-9098(199910)72:2<60::AID-JSO3>3.0.CO;2-1

10.1038/sj.bjc.6690081

10.1016/S1091-255X(98)80019-X

10.1245/s10434-017-6047-4

10.1245/s10434-018-07140-7

10.1245/s10434-016-5487-6

10.1002/jso.23356

10.1002/jso.25277

10.1245/s10434-019-08141-w

10.1245/s10434-019-08139-4

10.1001/jama.2012.385

10.1245/s10434-020-09161-7

10.1001/jamaoncol.2016.3797

10.1001/jamasurg.2018.0996

10.1136/esmoopen-2020-000944

10.1016/j.surg.2015.09.013

10.18632/oncotarget.7638

10.4103/jcrt.jcrt_280_21

10.1038/nature14581

10.1245/s10434-020-09007-2

Thông tin
Thông tin xuất bản

Ca-A Cancer Journal for Clinicians

Tập 73 Số 1

49-71

Thông tin tác giả